Answers are grounded in this paper and cite their sources.
Cross-sectional study evaluates in-vitro activity of ceftazidime-avibactam against resistant bacteria, suggesting potential treatment options.
Escalating antimicrobial resistance is a global threat, emphasizing the need to explore alternative treatment options. Hence, we aimed to explore the in-vitro activity of ceftazidime-avibactam (CAZ-AVI) in clinical isolates of carbapenem-resistant gram-negative bacteria.
No takes yet. Share an insight, caveat, or question.
Ahsan et al. (2025) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: